Higher serum level of CTRP15 in patients with coronary artery disease is associated with disease severity, body mass index and insulin resistance. (2nd January 2022)

• Record Type: Journal Article
• Authors: Shokoohi Nahrkhalaji, Abolfazl; Ahmadi, Reza; Fadaei, Reza; Panahi, Ghodratollah; Razzaghi, Malihe; Fallah, Soudabeh
• Is Part Of: Archives of physiology and biochemistry. Volume 128:Number 1(2022)
• Page Start: 276
• Page End: 280
• Publication Date: 2022-01-02
• Subjects: CTRP -- adiponectin -- atherosclerosis -- adipose tissue -- inflammation; Physiology -- Periodicals; Biochemistry -- Periodicals; Biophysics -- Periodicals; Biochemistry; Physiology; 571
• DOI: 10.1080/13813455.2019.1675713
• Languages: English
• ISSNs: 1381-3455

Abstract

Abstract: Background: CTRP15 is a prologue of adiponectin which has shown to have favourable effects on glucose and lipid metabolism. Studies have reported lower levels of CTRP15 in T2DM and metabolic syndrome; however, its circulating levels have not been evaluated in CAD patients. Methods: This case–control study was conducted on 190 angiographically confirmed coronary artery disease (CAD) patients and 70 controls. Serum levels of CTRP15, adiponectin, TNF-α, and IL-6 were measured using the ELISA technique. Results: CTRP15 was shown to occur in higher levels in CAD patients compared with controls. In CAD patients, CTRP15 showed a positive correlation with BMI, FBS, insulin, HOMA-IR, IL-6, and TNF-α and a negative correlation with HDL-C and adiponectin. Conclusion: Elevated levels of CTRP15 in CAD patients and the relation of CTRP15 with pathogenic conditions such as insulin resistance, inflammation, and decreased adiponectin and HDL-C suggest a possible compensatory response to these conditions in CAD patients.